Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...

The clinical-stage company on Monday said that, following "highly encouraging" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a ...

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today ...

INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.

Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have ...

Scientists say a combo of robotics and spinal stimulation has restored some movement in paralysis for the first time.

Spinal cord injuries are life-altering, often leaving individuals with severe mobility impairments. While rehabilitation ...